Antimycobacterial activity some different lamiaceae plant extracts containing flavonoids and other phenolic compounds
| dc.authorid | 0000-0002-2700-1965 | en_US |
| dc.contributor.author | Aşkun, Tülin | |
| dc.contributor.author | Tümen, Gülendam | |
| dc.contributor.author | Satıl, Fatih | |
| dc.contributor.author | Modanlıoğlu, Şeyma | |
| dc.contributor.author | Yalçın, Onur | |
| dc.date.accessioned | 2019-10-17T11:40:33Z | |
| dc.date.available | 2019-10-17T11:40:33Z | |
| dc.date.issued | 2012 | en_US |
| dc.department | Fakülteler, Fen-Edebiyat Fakültesi, Biyoloji Bölümü | en_US |
| dc.description | Aşkun, Tülin (Balikesir Author) | en_US |
| dc.description.abstract | Mycobacterium tuberculosis is a pathogenic bacteria species of the genus Mycobacterium, first discovered in 1882 by Robert Koch, which causes tuberculosis (TB) (Ryan & Ray, 2004). The disease is characterized by symptoms such as sepsis, septic shock, multiple organ failure (Muckart & Bhagwanjee, 1997). It may spread to the central nervous system and cause TB meningitis, intracranial tuberculomas, or abscesses (Harisinghani et al., 2000; Hwang et al., 2010). After the late 1980s, tuberculosis morbidity and mortality rates became a major health problem for industrialized countries (Raviglione et al., 1995; Heym & Cole, 1997). Multidrug-resistant tuberculosis (MDR TB) and extensively drug resistant tuberculosis (XDR TB) has become a common phenomenon, which cause drugs to be ineffective. MDRTB results from either primary infection or may develop in the course of a patient's treatment. MDR TB is resistant to at least two first-line anti-TB drugs, isoniazid (INH) and rifampicin (RIF), which are most powerful anti-TB drugs; XDR TB is resistant to INH and RIF, plus fluoroquinolone and at least one of three injectable second-line drugs such as capreomycin, kanamycin, and amikacin. Treatment of XDR-TB is not possible by first-line anti-TB drugs, which are less effective, expensive and toxic; in addition treatment takes two years or more (WHO, 2011a; WHO, 2011b). | en_US |
| dc.identifier.endpage | 336 | en_US |
| dc.identifier.startpage | 309 | en_US |
| dc.identifier.uri | https://hdl.handle.net/20.500.12462/8671 | |
| dc.identifier.wos | WOS:000374244100015 | |
| dc.identifier.wosquality | N/A | |
| dc.indekslendigikaynak | Web of Science | |
| dc.language.iso | en | en_US |
| dc.publisher | Intech Europe | en_US |
| dc.relation.ispartof | Understanding Tuberculosis - New Approaches To Fighting Against Drug Resistance | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.title | Antimycobacterial activity some different lamiaceae plant extracts containing flavonoids and other phenolic compounds | en_US |
| dc.type | Article | en_US |












